<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.0 20120330//EN" "JATS-journalpublishing1.dtd">
<article article-type="abstract" dtd-version="1.0" xml:lang="en" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">CC</journal-id>
<journal-id journal-id-type="nlm-ta">Cardiol Croat</journal-id>
<journal-title-group>
<journal-title>Cardiologia Croatica</journal-title>
<abbrev-journal-title abbrev-type="pubmed">Cardiol. Croat.</abbrev-journal-title>
</journal-title-group>
<issn pub-type="ppub">1848-543X</issn>
<issn pub-type="epub">1848-5448</issn>
<publisher><publisher-name>Croatian Cardiac Society</publisher-name></publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="publisher-id">CC_13(11-12)_307</article-id>
<article-id pub-id-type="doi">10.15836/ccar2018.307</article-id>
<article-categories><subj-group subj-group-type="heading"><subject>Extended Abstract</subject></subj-group>
</article-categories>
<title-group>
<article-title>High-intensity statin therapy in patients with acute coronary&#x2028;syndrome: is it enough to achieve target values?</article-title>
<trans-title-group xml:lang="HR">
<trans-title>Intenzivirana terapija statinima u bolesnika s akutnim&#x2028;koronarnim sindromom: posti&#x017E;emo li ciljne vrijednosti?</trans-title>
</trans-title-group>
</title-group>
<contrib-group>
<contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-8664-3338</contrib-id><name><surname>Planini&#x0107;</surname><given-names>Zrinka</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="corresp" rid="cor1">*</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-5989-6495</contrib-id><name><surname>Pa&#x0161;ali&#x0107;</surname><given-names>Ante</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-3189-8661</contrib-id><name><surname>Fri&#x0161;&#x010D;i&#x0107;</surname><given-names>Tea</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-7904-8899</contrib-id><name><surname>Per&#x010D;i&#x0107;</surname><given-names>Marko</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-8502-7816</contrib-id><name><surname>Gulin</surname><given-names>Dario</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-0555-6863</contrib-id><name><surname>Adrovi&#x0107;</surname><given-names>Leon</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-4488-0559</contrib-id><name><surname>&#x0160;iki&#x0107;</surname><given-names>Jozica</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="aff" rid="aff2"><sup>2</sup></xref></contrib>
<aff id="aff1"><label>1</label>Klini&#x010D;ka bolnica &#x201C;Sveti Duh&#x201D;, Zagreb, Hrvatska,</aff>
<aff id="aff2"><label>2</label>Sveu&#x010D;ili&#x0161;te u Zagrebu, Medicinski fakultet, Zagreb, Hrvatska</aff>
<aff id="aff3"><label>1</label><institution>University Hospital &#x201E;Sveti Duh&#x201C;</institution>, <addr-line>Zagreb</addr-line>, <country>Croatia</country></aff>
<aff id="aff4"><label>2</label><institution>University of Zagreb School of Medicine</institution>, <addr-line>Zagreb</addr-line>, <country>Croatia</country></aff>
</contrib-group>
<author-notes>
<corresp id="cor1"><label>*</label>ADDRESS FOR CORRESPONDENCE: Zrinka Planini&#x0107;, Klini&#x010D;ka bolnica &#x201C;Sveti Duh&#x201D;, Sveti Duh 64, HR-10000 Zagreb, Croatia. / Phone: +385-99-2299-249 / E-mail: <email xlink:href="zrinkaplaninic@gmail.com">zrinkaplaninic@gmail.com</email></corresp></author-notes>
<pub-date pub-type="epub-ppub"><month>11</month><year>2018</year></pub-date>
<volume>13</volume>
<issue>11-12</issue>
<fpage>307</fpage>
<lpage>308</lpage>
<history>
<date date-type="received"><day>17</day><month>10</month><year>2018</year></date><date><day>05</day><month>11</month><year>2018</year></date>
</history>
<permissions>
<copyright-year>2018</copyright-year>
<copyright-holder>Croatian Cardiac Society</copyright-holder>
</permissions>
<kwd-group kwd-group-type="translator" xml:lang="HR"><kwd>KLJU&#x010C;NE RIJE&#x010C;I: hiperlipidemija</kwd><kwd>akutni koronarni sindrom</kwd><kwd>LDL kolesterol</kwd></kwd-group>
<kwd-group kwd-group-type="author"><title>KEYWORDS: </title><kwd>hyperlipidemia</kwd><kwd>acute coronary syndrome</kwd><kwd>low density lipoprotein cholesterol</kwd></kwd-group>
</article-meta>
</front>
<body>
<p><bold>Introduction</bold>: Hyperlipidemia is a major risk factor for coronary heart disease. Early treatment of hyperlipidemia following acute coronary syndrome (ACS) provides potential benefits. According to ESC Guidelines for the Management of Dyslipidaemias (<xref ref-type="bibr" rid="r1"><italic>1</italic></xref>), it is recommended to initiate a high-dose statin therapy early after admission in all ACS patients, regardless of initial low-density lipoprotein cholesterol (LDL-C) values, with the aim of reaching the LDL-C goal &lt; 1.8 mmol/L or at least a 50% reduction of LDL-C if the baseline is between 1.8 and 3.5 mmol/L. (<xref ref-type="bibr" rid="r1"><italic>1</italic></xref>, <xref ref-type="bibr" rid="r2"><italic>2</italic></xref>) The latest results of EUROASPIRE V study showed that even though the majority of patients with ACS were receiving lipid-lowering therapy, only about one in three of these patients attained the recommended LDL-C goal values. The aim of this study was to investigate how many patients discharged with the diagnosis of ACS reach the recommended LDL-C goal values at 3-month follow-up.</p>
<p><bold>Patients and Methods</bold>: We retrospectively analyzed 206 patients discharged with a diagnosis of ACS: 90 patients (44%) had ST-segment elevation myocardial infarction, 86 (42%) had no ST-segment elevation myocardial infarction, and 30 (14%) had unstable angina pectoris. Among patients diagnosed with ACS, 66% were men and 34% were women, with a mean age of 66.13 years old. All patients received high-dose statin therapy (atorvastatin 80 mg or rosuvastatin 40 mg), a few of them even in combination with ezetimibe. We analyzed the baseline LDL-C values during hospital admission and after discharge at 3-month follow-up.</p>
<p><bold>Results</bold>: The average LDL-C value during hospital admission was 3.36 mmol/L, considering that 28% of patients already had some type of lipid-lowering therapy. At 3-month follow-up the average LDL-C value was 2.19 mmol/L. The target level of LDL-C &lt; 1.8 mmol/L was attained by 38% of patients (<xref ref-type="fig" rid="f1"><bold>Figure 1</bold></xref>).</p>
<fig id="f1" position="float" fig-type="figure"><label>FIGURE 1</label><caption><p>Therapy effect on LDL-cholesterol reduction. LDL-C = LDL cholesterol.</p></caption><graphic xlink:href="CC_13(11-12)_307-f1"></graphic></fig>
<p><bold>Conclusion</bold>: Only 38% of patients with ACS reached the LDL-C target at 3-month follow-up despite recommended therapy, which correlates with EUROASPIRE V findings. The poor goal attainment might be due to poor dietary habits and inadequate lifestyle. Therefore, we need to improve lipid management in ACS patients in secondary prevention.</p>
</body>
<back>
<ref-list>
<title>LITERATURE</title>
<ref id="r1"><label>1</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Catapano</surname><given-names>AL</given-names></name><name><surname>Graham</surname><given-names>I</given-names></name><name><surname>De Backer</surname><given-names>G</given-names></name><name><surname>Wiklund</surname><given-names>O</given-names></name><name><surname>Chapman</surname><given-names>MJ</given-names></name><name><surname>Drexel</surname><given-names>H</given-names></name><etal/><collab>ESC Scientific Document Group</collab></person-group>. <article-title>2016 ESC/EAS Guidelines for the Management of Dyslipidaemias.</article-title> <source>Eur Heart J</source>. <year>2016</year> Oct 14;<volume>37</volume>(<issue>39</issue>):<fpage>2999</fpage>&#x2013;<lpage>3058</lpage>. <pub-id pub-id-type="doi">10.1093/eurheartj/ehw272</pub-id><pub-id pub-id-type="pmid">27567407</pub-id></mixed-citation></ref>
<ref id="r2"><label>2</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Balci</surname><given-names>B</given-names></name></person-group>. <article-title>The modification of serum lipids after acute coronary syndrome and importance in clinical practice.</article-title> <source>Curr Cardiol Rev</source>. <year>2011</year> Nov;<volume>7</volume>(<issue>4</issue>):<fpage>272</fpage>&#x2013;<lpage>6</lpage>. <pub-id pub-id-type="doi">10.2174/157340311799960690</pub-id><pub-id pub-id-type="pmid">22758629</pub-id></mixed-citation></ref>
</ref-list>
</back>
</article>
